MX363662B - Métodos para incrementar la sensibilidad a insulina mediante agonistas de receptores serotonérgicos 5-ht2. - Google Patents

Métodos para incrementar la sensibilidad a insulina mediante agonistas de receptores serotonérgicos 5-ht2.

Info

Publication number
MX363662B
MX363662B MX2012011700A MX2012011700A MX363662B MX 363662 B MX363662 B MX 363662B MX 2012011700 A MX2012011700 A MX 2012011700A MX 2012011700 A MX2012011700 A MX 2012011700A MX 363662 B MX363662 B MX 363662B
Authority
MX
Mexico
Prior art keywords
insulin
sensitivity
increasing
receptor antagonists
receptor
Prior art date
Application number
MX2012011700A
Other languages
English (en)
Other versions
MX2012011700A (es
Inventor
Hong Chong Enrique
María De Lourdes Medina Contreras Juana
Original Assignee
Centro De Investig Y De Estudios Avanzados Del I P N Star
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro De Investig Y De Estudios Avanzados Del I P N Star filed Critical Centro De Investig Y De Estudios Avanzados Del I P N Star
Priority to MX2012011700A priority Critical patent/MX363662B/es
Priority to PCT/IB2013/059161 priority patent/WO2014057408A1/en
Publication of MX2012011700A publication Critical patent/MX2012011700A/es
Publication of MX363662B publication Critical patent/MX363662B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a la participación de receptores serotonérgicos 5-TH2 con el incremento en la sensibilidad a la insulina, principalmente por aumentar la captura periférica de glucosa. La presente invención tiene como objetivo principal la utilización de agonistas de receptores serotonérgicos 5-HT2, como por ejemplo indorrenato (agente hipertensivo que actúa como agonista de receptores 5-HT1A centrales) en composiciones farmacéuticas para mejorar la sensibilidad a la insulina, al actuar como agonista 5-HT2 en la periferia.
MX2012011700A 2012-10-08 2012-10-08 Métodos para incrementar la sensibilidad a insulina mediante agonistas de receptores serotonérgicos 5-ht2. MX363662B (es)

Priority Applications (2)

Application Number Priority Date Filing Date Title
MX2012011700A MX363662B (es) 2012-10-08 2012-10-08 Métodos para incrementar la sensibilidad a insulina mediante agonistas de receptores serotonérgicos 5-ht2.
PCT/IB2013/059161 WO2014057408A1 (en) 2012-10-08 2013-10-07 Methods for increasing insulin sensitivity by agonists of serotonergic receptors 5-ht2

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2012011700A MX363662B (es) 2012-10-08 2012-10-08 Métodos para incrementar la sensibilidad a insulina mediante agonistas de receptores serotonérgicos 5-ht2.

Publications (2)

Publication Number Publication Date
MX2012011700A MX2012011700A (es) 2014-04-25
MX363662B true MX363662B (es) 2019-03-27

Family

ID=49917193

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012011700A MX363662B (es) 2012-10-08 2012-10-08 Métodos para incrementar la sensibilidad a insulina mediante agonistas de receptores serotonérgicos 5-ht2.

Country Status (2)

Country Link
MX (1) MX363662B (es)
WO (1) WO2014057408A1 (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9902047D0 (en) * 1999-01-29 1999-03-17 Cerebrus Ltd Chemical compounds XI
US20080103179A1 (en) 2006-10-27 2008-05-01 Tam Peter Y Combination Therapy
US7019010B2 (en) 2001-09-27 2006-03-28 Novertis Ag Combinations
WO2006132196A1 (ja) 2005-06-08 2006-12-14 Asahi Kasei Pharma Corporation β３作動薬を含有する新規な医薬
WO2008122019A1 (en) 2007-04-02 2008-10-09 Cypress Biosciences, Inc. Improving the tolerability of both mirtazapine and reboxetine by using them in combination

Also Published As

Publication number Publication date
WO2014057408A1 (en) 2014-04-17
MX2012011700A (es) 2014-04-25

Similar Documents

Publication Publication Date Title
CR20150296A (es) Novedosos derivados de bencimidazol como antagonistas de ep4
PH12015501247A1 (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
SG195375A1 (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
UA111640C2 (uk) ПОХІДНІ [1,2,3]ТРИАЗОЛО[4,5-d]ПІРИМІДИНУ ЯК АГОНІСТИ КАНАБІНОЇДНОГО РЕЦЕПТОРА 2
EA201501122A1 (ru) Новые агонисты соматостатиновых рецепторов подтипа 4 (sstr4)
MY160665A (en) Spiropiperidine compounds as orl-1 receptor antagonists
MX2012012897A (es) Nuevos derivados de ciclohexilamina que tienen actividad como agonistas adrenergicos beta-2 y como antagonistas muscarinicos m3.
MX2014004387A (es) Nuevos derivados de ciclohexilamina que tienen actividad como agonistas adrenergicos b2 y como antagonistas muscarinicos m3.
BR112015012746A2 (pt) compostos que possuem atividade de antagonista de receptores muscarínicos e agonista de receptores beta2-adrenérgicos
EA201290355A1 (ru) Спиропиперидиновые соединения в качестве антагонистов рецептора orl-1
EA201390977A1 (ru) Комбинация агониста опиоидных рецепторов и антагониста опиоидных рецепторов для лечения болезни паркинсона
MX350419B (es) Compuesto (tieno [2,3-b] [1,5] benzoxazepin -4 -il) piperazin- 1 - ilo como angonistas inversos h1/antagonistas 5 -ht2a de actividad doble.
MX2014007042A (es) Composiciones de la buprenorfina y antagonistas de los receptores opioide-mu.
CR20140257A (es) Nuevos 2h-indazoles como antagonistas del receptor ep2
EA032937B1 (ru) Соединения, обладающие активностью антагонистов мускариновых рецепторов и агонистов бета-2 адренергических рецепторов
BR112013002846A2 (pt) derivados de tandospirona deuterada como agonista do receptor de 5-ht1a
MX341132B (es) Compuesto (tieno [2-3-b] [1,5] benzoxazepin-4-il) piperazin-1-ilo como agonista h1 inversos/antagonistas 5-ht2a de actividad doble.
MX2017015047A (es) Compuestos que tienen actividad antagonista del receptor muscarinico y actividad agonista del receptor beta2 adrenergico.
MX2012011700A (es) Metodo para incrementar la sencibilidad a insulina mediante agonista de receptores serotonergicos 5-ht2.
TN2013000429A1 (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
MX365594B (es) Compuestos de (tieno [2,3-b] [1,5] benzoxazepin-4-il) piperazin-1-ilo de actividad doble como agonista inversos de h1/antagonistas de 5-ht2a.
UA96048C2 (ru) Применение антагониста рецепторов интерлейкина-1 как средства фригопротекторного действия
UA96037C2 (ru) Применение антагониста рецепторов интерлейкина-1 как средства антиалкогольного действия
UA109581C2 (uk) Сполуки з активністю антагоністів мускаринових рецепторів і агоністів адренергічного рецептора бета2